ATE125626T1 - Cytokeratin-tumormarkierer und test zu deren nachweis. - Google Patents

Cytokeratin-tumormarkierer und test zu deren nachweis.

Info

Publication number
ATE125626T1
ATE125626T1 AT85900840T AT85900840T ATE125626T1 AT E125626 T1 ATE125626 T1 AT E125626T1 AT 85900840 T AT85900840 T AT 85900840T AT 85900840 T AT85900840 T AT 85900840T AT E125626 T1 ATE125626 T1 AT E125626T1
Authority
AT
Austria
Prior art keywords
test
detection
neoplastic
tumor marker
cytokeratin
Prior art date
Application number
AT85900840T
Other languages
English (en)
Inventor
Robert D Cardiff
Paul V Rossitto
Alan C Brabon
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24273031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE125626(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE125626T1 publication Critical patent/ATE125626T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eye Examination Apparatus (AREA)
AT85900840T 1984-01-06 1985-01-03 Cytokeratin-tumormarkierer und test zu deren nachweis. ATE125626T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56886284A 1984-01-06 1984-01-06

Publications (1)

Publication Number Publication Date
ATE125626T1 true ATE125626T1 (de) 1995-08-15

Family

ID=24273031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85900840T ATE125626T1 (de) 1984-01-06 1985-01-03 Cytokeratin-tumormarkierer und test zu deren nachweis.

Country Status (7)

Country Link
US (1) US4775620A (de)
EP (1) EP0167616B1 (de)
JP (5) JP2723203B2 (de)
AT (1) ATE125626T1 (de)
CA (1) CA1336171C (de)
DE (1) DE3588043T2 (de)
WO (1) WO1985003132A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR850552B (de) * 1984-03-07 1985-07-05 Du Pont
EP0242154B1 (de) * 1986-04-17 1993-03-03 Hybritech Incorporated Tumorassoziiertes Antigen
ATE92081T1 (de) * 1986-04-17 1993-08-15 Hybritech Inc Tumorassoziiertes antigen.
FR2606033B1 (fr) * 1986-10-31 1988-12-16 Cird Proteine cytoplasmique des cellules suprabasales de l'epiderme, anticorps capables de reconnaitre cette proteine, et lignees cellulaires hybrides capables de secreter de tels anticorps
FR2606034B1 (fr) * 1986-10-31 1989-06-02 Cird Nouvelle proteine de surface des cellules basales de l'epiderme, anticorps capables de reconnaitre cette proteine, et leur utilisation, et lignees cellulaires hybrides capables de secreter de tels anticorps
DE3815932A1 (de) * 1988-01-26 1989-08-03 Progen Biotechnik Gmbh Verfahren zur identifizierung des ursprungs einer zellgewebsprobe
US5660994A (en) * 1986-11-10 1997-08-26 Progen Biotechnik Gmbh Method of detecting tissue-specific, insoluble cytoskeletal proteins
DE3923951A1 (de) * 1989-07-19 1991-01-31 Boehringer Mannheim Gmbh Verfahren zum nachweis von leberzirrhose
US5411868A (en) * 1989-10-24 1995-05-02 Board Of Regents, The University Of Texas System Diagnostic and premonitoring uses of a 65 kDa tumor-associated protein in companion and domestic animal malignancy
DE3942999C2 (de) * 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4023945A1 (de) * 1990-07-27 1992-01-30 Progen Biotechnik Gmbh Verfahren zur reinigung von cytokeratin 20 und dessen verwendung zur erzeugung von antikoerpern
SE470273B (sv) * 1990-09-24 1993-12-20 Idl Immunodeveloplab Ab Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
US6890311B2 (en) 1997-09-16 2005-05-10 The Regents Of The University Of California Methods for performing medical procedures within a breast duct
WO1999041613A1 (en) 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
GB9905817D0 (en) * 1999-03-12 1999-05-05 Oxford Glycosciences Uk Ltd Methods
DE50015293D1 (de) * 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
WO2001013117A2 (en) * 1999-08-13 2001-02-22 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2001046697A2 (en) * 1999-12-21 2001-06-28 Millennium Predictive Medicine Identification, assessment, prevention, and therapy of breast cancer
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
DE10130985B4 (de) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
KR100978348B1 (ko) 2001-08-31 2010-08-26 케라텍 리미티드 가용성 ｓ-술폰화 케라틴 유도체로부터의 생체고분자 필름, 섬유, 발포체 및 접착제 재료의 제조
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US7630403B2 (en) * 2002-03-08 2009-12-08 Texas Instruments Incorporated MAC aggregation frame with MSDU and fragment of MSDU
US7297342B2 (en) * 2002-06-10 2007-11-20 Keratec Limited Orthopaedic materials derived from keratin
WO2004047774A1 (en) * 2002-11-28 2004-06-10 Keratec Limited Personal care formulations containing keratin
US7767756B2 (en) * 2003-09-19 2010-08-03 Keraplast Technologies, Ltd. Composite materials containing keratin
WO2005043166A1 (ja) * 2003-10-30 2005-05-12 Sysmex Corporation 子宮腺癌の診断薬及び腺癌細胞の検出方法
AU2004298392A1 (en) * 2003-12-19 2005-06-30 Keratec Limited Wound care products containing keratin
US7579317B2 (en) * 2005-03-11 2009-08-25 Keratec, Ltd. Nutraceutical composition comprising soluble keratin or derivative thereof
EP2064552B1 (de) * 2006-09-07 2011-08-31 Universitätsklinikum Hamburg-Eppendorf Verfahren für den nachweis karzinomatöser epithelzellen mittels freigesetzter zytokeratine als marker für diese zellen
WO2008070091A1 (en) * 2006-12-06 2008-06-12 Keratec, Ltd. Bone void fillers and methods of making the same
EP2099437A4 (de) * 2006-12-11 2013-06-19 Keratec Ltd Poröses keratin-konstrukt und herstellungsverfahren dafür
WO2008148109A1 (en) * 2007-05-24 2008-12-04 Keratec, Ltd. Porous keratin constructs, wound healing assemblies and methods using the same
KR20100129262A (ko) * 2007-10-31 2010-12-08 케라텍, 리미티드 케라틴 유도체 및 이의 제조 방법
US11090394B1 (en) 2012-03-27 2021-08-17 Florida A&M University Modified nanodelivery system and method for enhanced in vivo medical and preclinical imaging

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150149A (en) * 1976-11-29 1979-04-17 Professional Staff Association Of The Los Angeles County Harbor General Hospital Method and means for the early detection and diagnosis of certain types of cancers
US4229426A (en) * 1978-02-22 1980-10-21 Duke University, Inc. Breast cyst fluid protein assay
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
CA1190853A (en) * 1981-10-13 1985-07-23 Roberto L. Ceriani Method and compositions for carcinoma diagnosis
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy

Also Published As

Publication number Publication date
EP0167616B1 (de) 1995-07-26
EP0167616A4 (de) 1986-09-04
US4775620A (en) 1988-10-04
JP2723203B2 (ja) 1998-03-09
DE3588043T2 (de) 1996-03-21
JPH0681760B2 (ja) 1994-10-19
JPS6452800A (en) 1989-02-28
JPH08275778A (ja) 1996-10-22
CA1336171C (en) 1995-07-04
JPH10123138A (ja) 1998-05-15
EP0167616A1 (de) 1986-01-15
DE3588043D1 (de) 1995-08-31
JP2537539B2 (ja) 1996-09-25
JP2896362B2 (ja) 1999-05-31
WO1985003132A1 (en) 1985-07-18
JPS6447392A (en) 1989-02-21
JP2617289B2 (ja) 1997-06-04
JPS61501048A (ja) 1986-05-22

Similar Documents

Publication Publication Date Title
DE3588043D1 (de) Cytokeratin-tumormarkierer und test zu deren nachweis.
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
PL366575A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka jajnika
NO163986C (no) Fremgangsmaate for in vitro bedoemmelse av muligheten for cellekreft.
BR0008709A (pt) Método para diagnosticar diferencialmente emonitorar carcinomas malignos de mama
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DK0617124T3 (da) Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
DE3682780D1 (de) Mittel fuer die diagnose, die abbildung, die lokalisierung oder die behandlung von tumoren.
NO830570L (no) Antistoffer og antigener for diagnose og behandling av cancer
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
AU555699B2 (en) Pp13 protein from placenta
ES2033823T3 (es) Ensayo en cuanto a cancer de mama humano.
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
Tosca et al. Antigenic alterations in tumors of epidermal origin
ES538403A0 (es) Procedimiento para la obtencion de antipodas opticos del (+7-1,7-difenil-3-metilaza-7-ciano-8-metil-nonano
ATE61734T1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
DE3070210D1 (en) A process for preparing tumor antidotes (oncoclasines) from the excrements of goats
Mooney et al. Intermediate filament expression in carcinoid tumours
KURENUMA et al. A case report of ameloblastic fibroma Radiographic observation for 3 years and 8 months
Kamby et al. Differential influence of prognostic factors on the occurence of metastases at various anatomical sites in patients with breast cancer
Bezwoda et al. Tumour platelet derived growth factor (PDGF) expression predicts for shortened survival and treatment failure in advanced breast cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time